Target TBD TBD TBD TBD TBD Polyantipsychotic TBD Therapy Actual 33.6% 21% 27.3% Data Analysis: While justification has been a requirement for polyantipsychotic therapy (PAPT) it was completed on a case-by-case basis. It was decided to do so in a more formalized manner. This data represents the first step in developing that formalized process. Beginning in July, it was decided that data would be collected in a centralized manner and presented to the Pharmacy & Therapeutics to create a baseline data set of PAPT. For the quarter, 21% of patients at DDPC were receiving treatment with more than one antipsychotic, while 63% of the patients were receiving therapy during the quarter. Action Plan: DDPC will continue to develop the formalized PAPT tracking and reporting the findings to the Medical Director and prescribers at the facility. A formal, centralized process for PAPT will enable the facility to better optimize the patients’ therapies and identify trends and areas for improvement, all while striving for excellence in patient care. XI. Measure Name: Metabolic Monitoring Measure Description: Metabolic syndrome is a well-known side effect of second generation antipsychotics (SGAs) and represents a common comorbidity in the psychiatric population. The majority of patients prescribed antipsychotics are prescribed an entity from the SGA sub-class. The purpose of this is to ensure that DDPC is monitoring the patients it serves appropriately and to the best of its ability, while mitigating the consequences of metabolic syndrome as much as possible. Type of Measure: Performance Improvement Results Unit Baseline 1Q2017 2Q2017 3Q2017 4Q2017 YTD Target 50% 65% 70% 75% 75% Complete/ Up-to-date TBD Metabolic Parameters Actual 69.9% 85.7% 77.8%
Target Polyantipsychotic Therapy TBD TBD TBD TBD TBD TBD Actual 33.6% 21% 27.3% Data Analysis: While justification has been a requirement for polyantipsychotic therapy (PAPT) it was completed on a case-by-case basis. It was decided to do so in a more formalized manner. This data represents the first step in developing that formalized process. Beginning in July, it was decided that data would be collected in a centralized manner and presented to the Pharmacy & Therapeutics to create a baseline data set of PAPT. For the quarter, 21% of patients at DDPC were receiving treatment with more than one antipsychotic, while 63% of the patients were receiving therapy during the quarter. Action Plan: DDPC will continue to develop the formalized PAPT tracking and reporting the findings to the Medical Director and prescribers at the facility. A formal, centralized process for PAPT will enable the facility to better optimize the patients’ therapies and identify trends and areas for improvement, all while striving for excellence in patient care. XI. Measure Name: Metabolic Monitoring Measure Description: Metabolic syndrome is a well-known side effect of second generation antipsychotics (SGAs) and represents a common comorbidity in the psychiatric population. The majority of patients prescribed antipsychotics are prescribed an entity from the SGA sub-class. The purpose of this is to ensure that DDPC is monitoring the patients it serves appropriately and to the best of its ability, while mitigating the consequences of metabolic syndrome as much as possible. Type of Measure: Performance Improvement Results Unit Baseline 1Q2017 2Q2017 3Q2017 4Q2017 YTD Target Complete/ Up-to-date Metabolic Parameters TBD 50% 65% 70% 75% 75% Actual 69.9% 85.7% 77.8%
2Q2017.docx